Integral Molecular

Founded in 2001, Integral Molecular is a biotechnology company and industry leader in developing therapeutics targeting membrane proteins. As a result of that, Integral has over two decades of expertise in discovering, engineering, and characterizing therapeutic antibodies. Its technologies have been utilized or adopted by over 600 organizations across research, drug discovery, and vaccine development, and are described in more than 500 scientific publications and patents, including in Cell, Science, and Nature.

Integral Molecular has long played a defining role in antibody IP through its pioneering work in epitope mapping. As antibody patent law has evolved—most notably following Amgen v. Sanofi—Integral Molecular has led the field in developing a new, structure-based approach to antibody IP.

This next generation strategy is embodied in Paratope-PLUS™ Comprehensive CDR-Scanning, which experimentally defines the antibody paratope and all permissible CDR substitutions that retain binding. Developed in close collaboration with patent counsel, this approach enables structure-based genus claims that satisfy enablement and written description requirements, while also identifying improved variants for antibody engineering and generating high-throughput data for AI/ML applications.

Operating from a state-of-the-art research facility and supported by a deeply experienced scientific leadership team, Integral Molecular continues to bridge cutting-edge experimental biology with forward-looking intellectual property strategy and execution.